Live webinar on the use of generic, biosimilar and non-biologic complex drugs for multiple sclerosis
June 11 @ 3:30 pm – 4:30 pm
Register now!
Join this valuable and instructive webinar!
Familiarise yourself with the robust European regulatory processes and effective oversight for generic, biosimilar, and follow-on non-biologic complex drugs (NBCDs) of disease modifying therapies in multiple sclerosis that allow you to have informed conversations with your patients about the potential use of these agents.
Register now to gain insights from experts and ultimately optimize MS treatment strategies and improve patient outcomes!
The webinar takes place via Zoom, you will receive connection details upon registration.
The session will be held in English (translation in Spanish) on June 11th from 3:30 PM to 4:30 PM CEST.
Should you have specific questions, you would like to see discussed, please share them with learning@paradigms.foundation
Why participate?
- Learn about the regulatory requirements for generics, biosimilars and follow-on NBCD’s in Europe.
- Understand the clinical considerations for generics, biosimilars and follow-on NBCD’s in multiple sclerosis.
Who should join?
Neurologists who deal with multiple sclerosis (MS) treatment and management. Nurses working in the field of multiple sclerosis and patient representatives are also welcome to register.
Abstract
Because multiple sclerosis (MS) usually has an onset in early adulthood and is a progressive disease, the economic burden is substantial, and disease-modifying treatments (DMTs) constitute a large proportion of healthcare costs. The use of generic versions (of synthetic drugs), biosimilars (for biologics) or follow-on versions of non-biologic complex drugs (NBCDs) can reduce the overall cost of MS care and improve patient access.
In Europe, there are robust regulatory processes and effective oversight for generic, biosimilar and follow-on NBCDs of DMTs so that these agents can be considered interchangeable with the originator product. Physicians caring for patients with MS need to familiarise themselves with the evidence so that they can have informed conversations with their patients about the potential use of these agents.
OUR SPEAKERS
Celia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos, Madrid and Professor of Neurology at the University Complutense, Madrid, Spain.
After receiving her MD from the University Complutense, Madrid, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology, University of Munich, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany),Hospital de Fuenlabrada and at the University Hospital La Paz, both in Madrid.
Professor Oreja-Guevara’s research interests centre on family planning, menopause, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. Neuromyelitis optica (NMO) is among her other therapy areas of interest, and Professor Oreja-Guevara is actively involved in the evaluation of new drugs for the treatment of MS and NMO. As a principal investigator, she has participated in more than 30c MS clinical trials and currently heads Paradigms, an independent and non-profit international group of Multiple Sclerosis experts.
Besides her clinical and research endeavors, Professor Oreja-Guevara has held leadership roles in several neurology-focused organizations and academic societies, such as the Demyelinating Diseases Group and the Neuroimaging Group of the Spanish Neurological Society. Professor Oreja-Guevara is also Co-Chair of the Multiple Sclerosis Panel of the European Academy of Neurology (EAN), and serves as an expert for the European Medicines Agency (EMA) and the Spanish Agency of Medicines and Medicinal Products, highlighting her pivotal role in advancing neurology.
Thomas Berger, Professor of Neurology and Chair of the Dept. of Neurology at the Medical University of Vienna.
Thomas Berger, MD, MSc, FEAN, is Professor of Neurology and Chair of the Dept. of Neurology as well as Chair of the Comprehensive Center for Clinical Neurosciences & Mental Health at the Medical University of Vienna, Austria.
Scientific interests regard neuroimmunology, especially inflammatory demyelinating CNS disorders with a dedicated focus on body-fluid and imaging biomarker research in multiple sclerosis, NMOSD and MOGAD.
Moderator: Stefaan De Corte, General Manager, ParadigMS
REGISTRATION
Registration is necessary and can be completed by clicking the button on top of this page or here:
Please note: this is a live webinar primarily for neurologists from Europe, the Middle-East and North-Africa. Should you not fit this category and should we reach maximum capacity (100), we might cancel your registration.
OUR SPONSOR
This webinar is organised with the financial support of Sandoz. Sandoz was not involved in the elaboration of the presentations.
